← Back to screener

HALOZYME THERAPEUTICS, INC. HALO

Rank #1544 · Nasdaq · $15.5B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
46.5
P/E
55.1
P/B
91.45
ROE
165.8%
Op. Margin
40.7%
Debt Ratio
1001%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E 55.1x, P/B 91.45x. Ranks in the top 74% of the universe.

Profitability ★★★★★
Excellent

ROE 165.8%. Ranks in the top 4% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 1001%. Ranks in the top 91% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★☆
Excellent

Revenue growth of 25.6% year over year. Ranks in the top 14% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.1B$-0.1B$0.0B-427.6494
2012$0.0B$-0.1B$-0.1B$0.0B-398.2853
2013$0.1B$-0.0B$-0.0B$0.0B-35.4562
2014$0.0B$-0.1B$-0.1B$0.0B-126.7834
2015$0.1B$-0.1B$-0.1B$0.0B-146.8240
2016$0.1B$-0.1B$-0.1B$-0.0B-83.7-1009
2017$0.1B$-0.0B$-0.0B$0.0B-20.3532
2018$0.1B$-0.1B$-0.1B$0.0B-56.71109
2019$0.3B$0.1B$0.1B$-0.0B25.6-1455
2020$0.2B$-0.1B$-0.1B$0.2B-45.7172
2021$0.2B$-0.1B$-0.1B$0.2B-34.5133
2022$0.3B$0.1B$0.1B$0.1B53.91104
2023$0.4B$0.3B$0.4B$0.2B62.21107
2024$0.7B$0.3B$0.2B$0.2B40.5837
2025$0.8B$0.3B$0.3B$0.2B40.71001

← See the full screener